Back to top
more

Codexis (CDXS)

(Delayed Data from NSDQ)

$2.66 USD

2.66
513,446

+0.01 (0.38%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.65 -0.01 (-0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Codexis (CDXS) Surges 6.2%: Is This an Indication of Further Gains?

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

What Makes Codexis (CDXS) a New Strong Buy Stock

Codexis (CDXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Indrajit Bandyopadhyay headshot

3 Synthetic Biology Stocks in Focus With Strong Potential

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's What Could Help Codexis (CDXS) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?

Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.

Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca (AZN) Q2 Earnings In Line, Vaccine Aids Sales

AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.

Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

Strength Seen in Codexis (CDXS): Can Its 12.6% Jump Turn into More Strength?

Codexis (CDXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 30.00% and 21.09%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 37.50% and 22.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Codexis (CDXS) Q2 Earnings Expected to Decline

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Codexis (CDXS) Q1 Earnings Expected to Decline

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Mar 2, 2020

Companies in the news are: ALT, BIG, W, CDXS

Codexis (CDXS) Q4 Earnings and Revenues Lag Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -66.67% and -11.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Codexis (CDXS) Q3 Earnings and Revenues Beat Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 166.67% and 32.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?